查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963819

即時血糖值監測市場－全球產業規模、佔有率、趨勢、機會、預測：依產品類型、地區和競爭格局分類，2021-2031年

Point-of-Care Glucose Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球即時血糖監測市場預計將從 2025 年的 36.2 億美元成長到 2031 年的 46.8 億美元，複合年成長率為 4.37%。

此市場領域涵蓋可在醫院、診所和居家醫療等臨床環境中提供即時血糖分析的診斷設備和耗材。推動該領域成長的主要因素是生活方式相關代謝疾病的日益普遍以及全球人口的快速老化，這需要頻繁的健康監測。與技術趨勢不同，這些根本促進因素代表了結構性的人口和流行病學變化，需要分散式快速診斷解決方案來減輕中心檢查室基礎設施的負擔。

市場概覽
預測期 2027-2031
市場規模：2025年 36.2億美元
市場規模：2031年 46.8億美元
複合年成長率：2026-2031年 4.37%
成長最快的細分市場 AccuChek Inform II
最大的市場 北美洲

然而，阻礙市場擴張的一大障礙是嚴格的法規結構，該框架界定了設備的準確性和性能標準。這為製造商設定了很高的進入門檻。這些嚴格的合規要求可能導致產品核可延遲和研發成本增加，從而限制新解決方案進入消費者市場的速度。根據國際糖尿病聯盟 (IDF) 估計，到 2024 年，全球約有 5.89 億成年人將患有糖尿病。如此巨大的疾病負擔凸顯了開發便捷且合規的檢測方法的迫切需求，儘管監管壓力帶來了許多操作上的困難。

市場促進因素

持續血糖監測系統的技術進步正在從根本上改變全球照護現場血糖監測市場，以即時、基於感測器的追蹤取代間歇性毛細血管血檢測。這些創新顯著提高了患者的依從性和臨床療效，並透過預測性警報、延長感測器佩戴時間和無縫智慧型手機整合等功能，大幅降低了日常管理的侵入性。這種技術變革的商業性影響在基於感測器的平台快速成長中顯而易見。根據雅培公司2024年10月發布的2024年第三季財報顯示，其FreeStyle Libre持續血糖監測系統的銷售額達到16億美元，顯示市場對這些先進診斷技術有著大規模的需求。這種快速成長凸顯了用戶友善創新在推動照護現場領域擴張方面發揮的關鍵作用。

同時，隨著醫療保健系統將慢性病管理分散化，減輕醫院負擔，居家自我管理解決方案的採用率不斷提高，市場進入也不斷擴大。這種結構性轉變很大程度上是由於應對疾病日益成長的經濟影響的經濟需求而加速的，從而推動了經濟高效、患者可自行操作的診斷設備的普及。這種以患者為中心的模式的可行性體現在領先的居家醫療設備供應商的表現上。根據Dexcom於2024年10月發布的2024年第三季財報，季度營收達到9.942億美元，主要得益於自我管理生物感測器的普及。需要頻繁監測的患者群體不斷成長，進一步推動了這項轉變。世界衛生組織（WHO）於2024年11月發布的數據顯示，全球糖尿病成人患者人數已超過8億，這持續推高了對個人診斷設備的需求，並強化了醫療保健分散化的市場趨勢。

市場挑戰

醫療設備準確性和性能標準的嚴格法規結構是全球照護現場血糖檢測市場成長的主要障礙。製造商必須遵守複雜的合規程序並進行大規模臨床試驗，以滿足嚴格的安全標準。這項嚴苛的流程顯著提高了進入門檻，推高了研發成本，並延長了新產品的商業化時間。這些營運障礙阻礙了中小型創新企業進入該領域，減緩了檢測解決方案向消費者交付的速度。

因此，市場擴張速度難以滿足全球日益成長的分散式監測需求。對便利診斷工具的迫切需求與緩慢的監管核准之間存在差距，限制了經濟高效方案的普及。世界衛生組織（世衛組織）預測，到2024年，全球糖尿病患者人數將超過8億人。如此龐大的疾病負擔凸顯了法規核准延遲阻礙市場發展的巨大缺口，也使得市場未能充分利用日益成長的、需要即時血糖分析的患者群體。

市場趨勢

人工智慧 (AI) 和機器學習在預測分析領域的融合，正將血糖監測從被動應對轉變為主動預防。演算法透過分析過往模式預測血糖波動，從而為決策支援系統提供關鍵的預防性干預措施。這項功能能夠識別不利事件，並在其發生前就識別出來，從而提升臨床效用，並在精準醫療領域日益受到重視。根據發表於 2024 年 5 月 JMIR Medical Informatics 期刊的一篇題為「基於連續血糖監測的低血糖預測深度學習模型的泛化」的論文，基於長期記憶網路 (LSTM) 的深度學習模型在預測嚴重低血糖方面達到了 96.40% 的曲線下面積(AUC)。如此高的預測準確率使製造商能夠實現可靠的自動警報，從而增強用戶對下一代平台的信心。

無需處方箋的連續血糖生物感測器的出現，正從根本上改變著血糖監測的可及性，因為它將技術與處方要求脫鉤。這一趨勢的目標族群是那些透過改善生活方式而非依賴胰島素來管理代謝健康的龐大群體。透過消除監管障礙，製造商正將目標市場從核心的1型糖尿病患者群體擴展到糖尿病前期患者和健康管理用戶。根據Dekkom公司2024年3月發布的新聞稿《Dekkom Stero獲FDA核准成為首個商業化血糖生物感測器》，美國約有2,500萬2型糖尿病患者不使用胰島素，他們可以從這項技術中獲益。這種透過處方箋即可使用的淘汰實現的擴張，將有助於早期療育，並顯著提升該領域的商業性規模。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球即時血糖值監測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（AccuChek Aviva血糖機、OneTouch Verio Flex、i-STAT、拜耳Contour血糖監測系統、FreeStyle Lite、True Matrix、AccuChek InForm II、StatStrip、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美即時血糖值監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲即時血糖值監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區即時血糖值監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲即時血糖值監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲即時血糖值監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球即時血糖值監測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Inc.
  • Nipro Corporation
  • Lifescan, Inc.
  • Nova Biomedical Corporation
  • ACON Laboratories Inc.
  • Trividia Health, Inc.
  • Prodigy Diabetes Care, LLC
  • Ascensia Diabetes Care Holdings AG
  • EKF Diagnostics Holdings PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23979

The Global Point-of-Care Glucose Testing Market is projected to expand from USD 3.62 Billion in 2025 to USD 4.68 Billion by 2031, reflecting a compound annual growth rate of 4.37%. This market sector comprises diagnostic instruments and consumables designed to deliver immediate blood sugar analysis at the point of care, encompassing hospitals, clinics, and home healthcare settings. Growth is primarily underpinned by the escalating prevalence of lifestyle-induced metabolic disorders and a rapidly aging global population that requires frequent health monitoring. These foundational drivers are distinct from technological trends, representing structural demographic and epidemiological shifts that necessitate decentralized and rapid diagnostic solutions to alleviate the burden on central laboratory infrastructure.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.62 Billion
Market Size 2031USD 4.68 Billion
CAGR 2026-20314.37%
Fastest Growing SegmentAccu-Chek Inform II
Largest MarketNorth America

However, a significant challenge impeding broader market expansion is the stringent regulatory framework governing device accuracy and performance standards, which creates high barriers to entry for manufacturers. These rigorous compliance requirements can delay product approvals and increase development costs, thereby limiting the speed at which new solutions reach the consumer. According to the 'International Diabetes Federation', in '2024', approximately 589 million adults worldwide were estimated to be living with diabetes. This substantial disease burden underscores the critical necessity for accessible and compliant testing modalities, despite the operational difficulties imposed by regulatory pressures.

Market Driver

Technological advancements in Continuous Glucose Monitoring Systems are fundamentally reshaping the Global Point-of-Care Glucose Testing Market by replacing episodic capillary blood checks with real-time, sensor-based tracking. These innovations significantly enhance patient compliance and clinical outcomes through features like predictive alerts, extended sensor wear-time, and seamless smartphone integration, which collectively reduce the invasiveness of daily management. The commercial impact of this technological shift is evident in the rapid growth of sensor-based platforms; according to Abbott, October 2024, in the 'Third Quarter 2024 Financial Results', sales of the FreeStyle Libre continuous glucose monitoring system reached $1.6 billion, demonstrating the substantial market appetite for these advanced diagnostic technologies. This surge underscores the critical role of user-friendly innovation in driving the expansion of the point-of-care landscape.

Concurrently, the rising adoption of home-based self-monitoring solutions is broadening market access as healthcare systems decentralize chronic disease management to alleviate hospital burdens. This structural shift is heavily accelerated by the economic necessity of managing the condition's escalating financial impact, incentivizing the widespread deployment of cost-effective, patient-operated testing devices. The viability of this patient-centric model is reflected in the performance of major home-care device providers; according to Dexcom, October 2024, in the 'Third Quarter 2024 Financial Results', quarterly revenue reached $994.2 million, driven largely by the uptake of self-monitoring biosensors. This transition is further supported by the expanding patient pool requiring frequent monitoring; according to the World Health Organization, in November 2024, the number of adults living with diabetes worldwide surpassed 800 million, creating a sustained demand for personal diagnostic instruments and reinforcing the market's trajectory towards decentralized care.

Market Challenge

The stringent regulatory framework governing device accuracy and performance standards stands as a primary obstacle hampering the growth of the Global Point-of-Care Glucose Testing Market. Manufacturers must navigate complex compliance protocols and conduct extensive clinical trials to meet rigorous safety benchmarks. This demanding process creates substantial barriers to entry, inflating development costs and extending the timeline required to bring new products to commercial realization. These operational hurdles discourage smaller innovators from entering the sector and slow the pace at which testing solutions become available to consumers.

Consequently, the market struggles to scale rapidly enough to address the escalating global demand for decentralized monitoring. The disconnect between the urgent need for accessible diagnostic tools and the slow rate of regulatory approval restricts the availability of cost-effective options. According to the 'World Health Organization', in '2024', the number of adults living with diabetes worldwide surpassed 800 million. This magnitude of disease burden highlights the critical gap where regulatory delays prevent the market from fully capitalizing on the expanding patient base that requires immediate glucose analysis.

Market Trends

The integration of Artificial Intelligence and Machine Learning for predictive analytics is moving glucose monitoring from reactive to proactive. Algorithms now analyze historical patterns to forecast fluctuations, enabling preventative interventions critical for decision support systems. This capability enhances clinical utility by identifying adverse events before they occur, a feature increasingly demanded in precision medicine. According to JMIR Medical Informatics, May 2024, in the study 'Generalization of a Deep Learning Model for Continuous Glucose Monitoring-Based Hypoglycemia Prediction', a deep learning model based on long short-term memory networks achieved an Area Under the Curve of 96.40% for predicting severe hypoglycemia. This predictive accuracy allows manufacturers to deploy reliable automated alerts, increasing user trust in next-generation platforms.

The emergence of Over-the-Counter Continuous Glucose Biosensors is structurally shifting accessibility by decoupling technology from prescription requirements. This trend targets the massive demographic managing metabolic health through lifestyle modifications rather than insulin. By removing regulatory friction, manufacturers are expanding their addressable market beyond the core Type 1 diabetes population to include pre-diabetics and wellness users. According to Dexcom, March 2024, in the press release 'Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter', there are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from this technology. This non-prescription expansion facilitates earlier intervention, significantly broadening the sector's commercial scope.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Inc.
  • Nipro Corporation
  • Lifescan, Inc.
  • Nova Biomedical Corporation
  • ACON Laboratories Inc.
  • Trividia Health, Inc.
  • Prodigy Diabetes Care, LLC
  • Ascensia Diabetes Care Holdings AG
  • EKF Diagnostics Holdings PLC

Report Scope

In this report, the Global Point-of-Care Glucose Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-of-Care Glucose Testing Market, By Product Type

  • Accu Check Aviva Meter
  • Onetouch Verio Flex
  • i-STAT
  • Bayer CONTOUR Blood Glucose Monitoring System
  • Freestyle Lite
  • True Metrix
  • Accu-Chek Inform II
  • StatStrip
  • Others

Point-of-Care Glucose Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-of-Care Glucose Testing Market.

Available Customizations:

Global Point-of-Care Glucose Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-of-Care Glucose Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer CONTOUR Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Point-of-Care Glucose Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Point-of-Care Glucose Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
    • 6.3.2. Canada Point-of-Care Glucose Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
    • 6.3.3. Mexico Point-of-Care Glucose Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type

7. Europe Point-of-Care Glucose Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Point-of-Care Glucose Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
    • 7.3.2. France Point-of-Care Glucose Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
    • 7.3.3. United Kingdom Point-of-Care Glucose Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
    • 7.3.4. Italy Point-of-Care Glucose Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
    • 7.3.5. Spain Point-of-Care Glucose Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type

8. Asia Pacific Point-of-Care Glucose Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Point-of-Care Glucose Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
    • 8.3.2. India Point-of-Care Glucose Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
    • 8.3.3. Japan Point-of-Care Glucose Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
    • 8.3.4. South Korea Point-of-Care Glucose Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
    • 8.3.5. Australia Point-of-Care Glucose Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type

9. Middle East & Africa Point-of-Care Glucose Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Point-of-Care Glucose Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
    • 9.3.2. UAE Point-of-Care Glucose Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
    • 9.3.3. South Africa Point-of-Care Glucose Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type

10. South America Point-of-Care Glucose Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Point-of-Care Glucose Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
    • 10.3.2. Colombia Point-of-Care Glucose Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
    • 10.3.3. Argentina Point-of-Care Glucose Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Point-of-Care Glucose Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Nipro Corporation
  • 15.4. Lifescan, Inc.
  • 15.5. Nova Biomedical Corporation
  • 15.6. ACON Laboratories Inc.
  • 15.7. Trividia Health, Inc.
  • 15.8. Prodigy Diabetes Care, LLC
  • 15.9. Ascensia Diabetes Care Holdings AG
  • 15.10. EKF Diagnostics Holdings PLC

16. Strategic Recommendations

17. About Us & Disclaimer